A5027499943- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Genomic variations and chromosomal abnormalities
- Lung Cancer Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Ferroptosis and cancer prognosis
- CAR-T cell therapy research
- Cancer-related Molecular Pathways
- Immune Cell Function and Interaction
- Lung Cancer Research Studies
- Genetic factors in colorectal cancer
- Chromosomal and Genetic Variations
- Prenatal Screening and Diagnostics
- Gene expression and cancer classification
- Genomics and Rare Diseases
- Cancer-related molecular mechanisms research
- Cytokine Signaling Pathways and Interactions
- Genomics and Phylogenetic Studies
- Epigenetics and DNA Methylation
- Colorectal Cancer Treatments and Studies
- RNA modifications and cancer
- Cell Adhesion Molecules Research
- Molecular Biology Techniques and Applications
- Prostate Cancer Treatment and Research
LabCorp (United States)
2023-2025
Roswell Park Comprehensive Cancer Center
2014-2024
IQE (United Kingdom)
2018-2024
Mercy Research
2023
Thermo Fisher Scientific (United States)
2019
Center for Personalized Cancer Treatment
2014
Cancer Genetics (United States)
2004-2012
Fox Chase Cancer Center
2010
University at Buffalo, State University of New York
1992-2005
University Hospitals of Cleveland
1995-2000
Down syndrome is caused by a genomic imbalance of human chromosome 21 which mainly observed as trisomy 21. The regions on are syntenically conserved in three mouse chromosomes 10, 16 and 17. Ts65Dn mice, the most widely used model for syndrome, trisomic ∼56.5% syntenic region 16. To generate more complete we have established 22.9 Mb duplication spanning entire mice using Cre/ loxP -mediated long-range engineering. presence intact was confirmed fluorescent situ hybridization BAC-based array...
<h3>Background</h3> Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not all patients respond, and current biomarkers including PD-L1 mutational burden show incomplete predictive performance. The validity utility complex been studied in <h3>Methods</h3> Cutaneous metastatic melanoma at eight institutions were evaluated for expression, CD8<sup>+</sup> T-cell infiltration pattern, burden, 394 immune transcript expression. IHC assessed association...
The brain‐derived neurotrophic factor (BDNF), a neurotrophin fundamental for brain development and function, has previously been implicated in autism. In this study, the levels of BDNF platelet‐rich plasma were compared between autistic control children, role two genetic factors that might regulate contribute to autism etiology, NTRK2 , was examined. We found children ( n = 146) significantly higher t 6.82; P < 0.0001) than 50) positively correlated with platelet serotonin distribution r...
<h3>Background</h3> Resistance to immune checkpoint inhibitors (ICIs) has been linked local immunosuppression independent of major ICI targets (e.g., PD-1). Clinical experience with response prediction based on PD-L1 expression suggests that other factors influence sensitivity ICIs in non-small cell lung cancer (NSCLC) patients. <h3>Methods</h3> Tumor specimens from 120 NSCLC patients 10 institutions were evaluated for by immunohistochemistry, and global proliferative profile targeted...
PD-L1 immunohistochemistry (IHC) has been traditionally used for predicting clinical responses to immune checkpoint inhibitors (ICIs). However, there are at least 4 different assays and antibodies IHC, each developed with a ICI. We set test if next generation RNA sequencing (RNA-seq) is robust method determine mRNA expression levels furthermore, efficacy of response ICIs as compared routinely used, standardized IHC procedures.A total 209 cancer patients treated on-label by FDA-approved ICIs,...
CTLA-4 impedes the immune system's antitumor response. There are two Food and Drug Administration-approved anti-CTLA-4 agents - ipilimumab tremelimumab both used together with anti-PD-1/PD-L1 agents.
•VISTA expression differs among cancer types and there are diverse patterns.•High VISTA transcript correlates with high BTLA, TIM-3, TNFRSF14 expression.•High may predict poor immunotherapy survival in pancreatic patients.•Co-targeting co-expressed immunoregulatory molecules merit further investigation.•Tailored combined immune profiling warrants prospective studies. BackgroundOptimizing checkpoint inhibitor (ICI) therapy require identification of co-targetable pathways via profiling....
Significance Genetic alterations are frequently observed in bladder cancer. In this study, we demonstrate that tumors can be classified into two different types based on the spectrum of genetic diversity they confer. one class tumors, tumor protein p53 mutations and a large number single-nucleotide structural variants. Another characteristic group was chromosome shattering, known as chromothripsis, mutational heterogeneity. The other did not show these profound aberrations, but found novel...
We have developed a next-generation sequencing assay to quantify biomarkers of the host immune response in formalin-fixed, paraffin-embedded (FFPE) tumor specimens. This aims provide clinicians with comprehensive characterization immunologic microenvironment as guide for therapeutic decisions on patients solid tumors. The relies RNA-sequencing (seq) semiquantitatively measure levels 43 transcripts related anticancer responses and 11 that reflect relative abundance tumor-infiltrating...
Abstract Background Lymphocyte activation gene 3 (LAG‐3) or CD223 is a transmembrane protein that serves as an immune checkpoint which attenuates T‐cell activation. Many clinical trials of LAG‐3 inhibitors have had modest effects, but recent data indicate the antibody relatlimab, together with nivolumab (anti‐PD‐1), provided greater benefit than alone in patients melanoma. Methods In this study, RNA expression levels 397 genes were assessed 514 diverse cancers at clinical‐grade laboratory...
Abstract Background Cancer-testis antigens (CTAs) are tumor that normally expressed in the testes but aberrantly several cancers. CTA overexpression drives metastasis and progression of lung cancer, is associated with poor prognosis. To improve cancer diagnosis, prognostic prediction, drug discovery, robust identification quantitation needed. In this study, we examined quantified co-expression CTAs to derive testis antigen burden (CTAB), a novel biomarker immunotherapy response. Methods...
Recent studies have identified a new class of Prader-Willi syndrome (PWS) and Angelman (AS) patients who biparental inheritance, but neither the typical deletion nor uniparental disomy (UPD) or translocation. However, these DNA methylation throughout 15q11-q13, thus appear to mutation in imprinting process for this region. Here we describe detailed clinical findings five AS (three families) two PWS (one family). All essentially classical phenotype respective syndrome, except that incidence...
// Jianmin Wang 1,* , Antonios Papanicolau-Sengos 2,* Sreenivasulu Chintala 3,10,* Lei Wei 1 Biao Liu Qiang Hu Kiersten Marie Miles 2 Jeffrey M. Conroy Sean T. Glenn 4 Manuela Costantini 5,8,9 Cristina Magi-Galluzzi 6 Sabina Signoretti 7 Toni Choueiri Michele Gallucci 5 Steno Sentinelli Vito Fazio 8 Maria Luana Poeta 9 Song Carl Morrison and Roberto Pili 3,10 Department of Biostatistics & Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY, USA Pathology Center for Personalized...
Tumor antigen-driven selection may expand T cells having cell receptors (TCRs) of shared antigen specificity but different amino acid or nucleotide sequence in a process known as TCR convergence. Substitution sequencing errors introduced by TCRβ (TCRB) repertoire create artifacts resembling Given the anticipated differences substitution error rates across next-generation platforms, choice platform could be consequential. To test this, we performed TCRB on same peripheral blood mononuclear...
Immune checkpoint blockade is effective for only a subset of cancers. Targeting T-cell priming markers (TPMs) may enhance activity, but proper application these agents in the clinic challenging due to immune complexity and heterogeneity. We interrogated transcriptomics 15 TPMs (CD137, CD27, CD28, CD80, CD86, CD40, CD40LG, GITR, ICOS, ICOSLG, OX40, OX40LG, GZMB, IFNG, TBX21) pan-cancer cohort (N = 514 patients, 30 types cancer). TPM expression was analyzed correlation with histological type,...
Tissue-based broad molecular profiling of guideline-recommended biomarkers is advised for the therapeutic management patients with non-small cell lung cancer (NSCLC). However, practice variation can affect whether all indicated are tested. We aimed to evaluate impact common single-gene testing (SGT) on subsequent comprehensive genomic (CGP) test outcomes and results in NSCLC.